IBB:NSD-iShares Biotechnology ETF (USD)

ETF | Health |

Last Closing

USD 144.8

Change

+0.03 (+0.02)%

Market Cap

USD 7.60B

Volume

0.79M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
PPH VanEck Pharmaceutical ETF

-0.52 (-0.55%)

USD 0.72B
BBH VanEck Biotech ETF

+0.04 (+0.02%)

USD 0.45B
PSCH Invesco S&P SmallCap Health Ca..

-0.06 (-0.13%)

USD 0.20B
PTH Invesco DWA Healthcare Momentu..

-0.13 (-0.28%)

USD 0.15B
GNOM Global X Genomics & Biotechnol..

-0.02 (-0.18%)

USD 0.08B
FTXH First Trust Nasdaq Pharmaceuti..

-0.08 (-0.28%)

USD 0.02B
CNCR Loncar Cancer Immunotherapy ET..

-0.08 (-0.54%)

USD 0.01B

ETFs Containing IBB

IBB3:LSE 300.12 % 0.00 %

N/A

N/A
HAC.A:CA 0.00 % 3.14 %

N/A

N/A
HAC:CA Global X Seasonal Rotatio.. 0.00 % 1.27 %

-0.04 (0%)

CAD 0.22B
IBBS:LSE -299.94 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.59% 38% F 63% D
Dividend Return 0.24% 60% D- 3% F
Total Return 6.83% 38% F 60% D-
Trailing 12 Months  
Capital Gain 20.49% 63% D 65% D
Dividend Return 0.37% 50% F 3% F
Total Return 20.86% 50% F 63% D
Trailing 5 Years  
Capital Gain 45.48% 63% D 70% C-
Dividend Return 1.60% 43% F 5% F
Total Return 47.08% 50% F 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 3.53% N/A N/A 53% F
Dividend Return 3.76% N/A N/A 50% F
Total Return 0.24% N/A N/A 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 20.02% N/A N/A 76% C+
Risk Adjusted Return 18.78% N/A N/A 53% F
Market Capitalization 7.60B 100% F 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike